Skip to main
ACET

ACET Stock Forecast & Price Target

ACET Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adicet Bio is anticipated to have a positive outlook, backed by its promising product pipeline of allogeneic gamma delta T cell therapies, including prulacabtagene leucel for autoimmune diseases and ADI-212 for prostate-specific membrane antigen. Additionally, its preliminary Phase 1 data for prula-cel has shown significant efficacy and a benign safety profile in treating lupus nephritis and systemic lupus erythematosus, with potential for future upside in other autoimmune indications. Multiple key data updates are expected in 2026, including the initiation of a Phase 1 study for ADI-212 in metastatic castration-resistant prostate cancer.

Bears say

Adicet Bio is facing a number of fundamental risks that may hinder the potential success of its main product candidate, prulacabtagene leucel (prula-cel), in treating autoimmune diseases. These include potential shortcomings in both efficacy and safety, as well as competition from other companies developing similar CD19-targeted CAR-T agents. Additionally, regulatory and manufacturing risks could lead to delays or roadblocks in the development and commercialization of Adicet's pipeline. All of these factors contribute to the overall negative outlook for Adicet Bio's stock.

ACET has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adicet Bio, Inc. (ACET) Forecast

Analysts have given ACET a Strong Buy based on their latest research and market trends.

According to 3 analysts, ACET has a Strong Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adicet Bio, Inc. (ACET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.